Study Finds Age-Related Macular Degeneration Progression Predictors


Investigators found an association between disease progression change in done dark adaptation, yellow-blue, chromatic threshold and foveal thickness.


Change in done dark adaptation (cone τ), yellow-blue (YB) chromatic threshold and foveal thickness are all independent predictors of likely risk of age-related macular degeneration (AMD) disease progression, according to a new report.

Investigators from Cardiff University in the UK recruited 100 patients AMD to evaluate the likely risk of progression from early and intermediate to advanced AMD. Additionally, 60% of the patients came from a clinical trial cohort.

The investigators used the Age-Related Eye Disease Study (AREDS) simplified scale to study risk of progression. This scale ranges from 0-4 and exhibits a 0.5% and 50% chance, respectively, of the progression to advanced AMD over a five-year period. The investigators also wanted to use this study to determine what the relationship was between disease severity and the observed functional and structural deficits.

The patients’ AMD status varied from early to advanced. They were recruited from the Bristol Eye Hospital between July 2014 and August 2016. All participants were between the ages of 55 and 88 years old. The investigators tested the patients’ visual function using cone dark adaptation, 14 Hz flicker and chromatic threshold tests. They also measured retinal structure using drusen volume and macular thickness.

The mean age of the patients in the grade 0 group (69 years) was significantly lower than grades 2 (76), 3 (78), and 4 (77), the study authors found.

The investigators learned that cone τ and YB chromatic sensitivity were independent predictors for AMD progression risk.

“With every log minute increase in cone τ and every 1-unit increase in the CAD threshold, the odds of moving up a severity grade were increased by 28.56 and 4.09 times, respectively,” they wrote.

They added that both of these were the best functional tests for distinguishing between the severity of disease among the patients tested. Drusen characteristics were also able to be used to show differences between participants with early compared to advanced AMD, but were not able to then go on to show differences between those with early AMD and control patients.

The team also found that the only structural predictor was foveal thickness. There were differences in retinal thickness between severity groups when the investigators looked at the foveal and inner subgroups. The mean foveal subfield was significantly thicker in those graded zero when compared to the grade-4 group, the investigators said.

“Using the AREDS Simplified scale as a surrogate, cone dark adaptation was found to be the best predictor of risk of AMD progression,” the study authors concluded. “Of the remaining 3 functional tests, YB chromatic sensitivity had the greatest value as a marker of AMD progression risk. “

Investigators also found that chronic sensitivity was best at distinguishing between AMD severity, as well as showing the closest relationship to retinal structural change.

Though this study evaluated ability to predict risk of disease progression using biomarkers, there still remains a need for longitudinal evaluation of these functional measures for the long-term, definitive quantification of this risk, the study authors said.

The paper, titled “An Evaluation of a Battery of Functional and Structural Tests as Predictors of Likely Risk of Progression of Age-Related Macular Degeneration,” was published in the journal IOVS: Investigative Ophthalmology & Visual Science.

Related Videos
Cindy X. Cai, MD: Impact of Race, Neighborhood on Diabetic Retinopathy Care | Image Credit: Johns Hopkins University
Dimitra Skondra, MD, PhD: Protective Effect of Metformin in Geographic Atrophy| Image Credit: University of Chicago
Deepak Sambhara, MD | Image Credit: American Society of Retina Specialists
Sean Adrean, MD: Impact of Baseline VA on Aflibercept 8 mg Outcomes in DME | Image Credit: Linkedin
Mark Barakat, MD: Stable IOP Outcomes After Aflibercept 8 mg in DME | Image Credit: Retina Macula Institute of Arizona
Primary Care Roles in Alzheimer Diagnosis, with Theresa Sivers-Teixeira, MSPA, PA-C
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
Etienne Sibille, PhD: Innovations in Cognitive Pathology
Roger Goldberg, MD: Impact of Dual Inhibition on Hard Exudates in DME | Image Credit: Bay Area Retina Associates
Deepayan Kar, PhD, MS: A Virtual Reality Approach to Contrast Sensitivity in AMD | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.